# Beraprost-314d Added-on to Tyvaso® (BEAT)

> **NCT01908699** · PHASE3 · COMPLETED · sponsor: **Lung Biotechnology PBC** · enrollment: 273 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Beraprost Sodium 314d Modified Release Tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01908699
- **Lead sponsor:** Lung Biotechnology PBC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-31
- **Primary completion:** 2019-02-19
- **Final completion:** 2019-02-19
- **Target enrollment:** 273 (ACTUAL)
- **Last updated:** 2020-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01908699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01908699, "Beraprost-314d Added-on to Tyvaso® (BEAT)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01908699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*